Myeloma Super Responders: What HealthTree Registry Data Reveals | IMS 2026

Does High Blood Sugar Affect CAR-T Outcomes in Multiple Myeloma? | IMS 2026

PERSEUS 6-Year Results: D-VRd Improves Myeloma PFS & Supports Dual Maintenance | IMS 2026

Can Myeloma Be Cured Even After Relapse? | IMS 2026

AI and Myeloma: HealthTree Research Finds a Fixable Problem With M-Protein Data | IMS 2026

CMV Reactivation After CAR-T: Who Is at Risk? | IMS 2026

Supplements in Myeloma, MGUS & SMM: HealthTree Survey Results & Future Research | IMS 2026

Does Tec-Dara Help Myeloma Patients Live Longer? | IMS 2026

Mass Spectrometry in Myeloma: Can a Blood Test Reduce Bone Marrow Biopsies? | IMS 2026

Can Resistance Exercise Help Heal Bone Lesions in Multiple Myeloma? | IMS 2026

Can CD4/CD8 T-Cell Ratio Predict Parkinson-Like Side Effects After BCMA CAR-T in Myeloma | IMS 2026

Can Iberdomide Replace Revlimid in Newly Diagnosed Myeloma? KId Results | IMS 2026

MajesTEC-3: Could Teclistamab + Daratumumab Lead to a “Functional Cure” in Myeloma? | IMS 2026

Infection Prevention in Multiple Myeloma: What Patients Need to Know | IMS 2026

MajesTEC-5: High MRD-Negative Rates With Talquetamab Combo in Newly Diagnosed Myeloma | IMS 2026

Top 5 Things Newly Diagnosed Multiple Myeloma Patients Should Know | IMS 2026

CARTITUDE-2: Can Earlier Cilta-Cel CAR-T Lead to Long-Term Remission or Cure in Myeloma? | IMS 2026

ENDURANCE Trial: Can Myeloma Patients Stop Revlimid Maintenance After 2 Years? | IMS 2026

Iberdomide Plus Dara After Transplant: Early Safety and Results | IMS 2026